Longport, Inc. Announces Third Quarter 2008 Sales Activity
08 10월 2008 - 12:30AM
Business Wire
Longport, Inc. (OTC PK:LPTI), a medical technology specialist in
high-frequency high resolution ultrasound imaging, today announced
information on orders received since the beginning of 2008. Sales
activity by the end of the third quarter has totaled 33 EPISCAN
systems. All of the units have been sold into wound
prevention/assessment. Of the last ten sales, 3 systems were into
long-term care, and 7 systems were sold into acute hospitals. Sales
into acute hospitals were a direct result of the new CMS Ruling,
which has now gone into effect. This CMS rule change states that
Medicaid and Medicare will no longer be held responsible for
�reasonably preventable� hospital-acquired pressure ulcers. This
rule is expected to benefit Longport�s efforts in getting the
EPISCAN I-200 ultrasound scanner accepted in hospitals for use in
pressure ulcer prevention. The EPISCAN is an assessment tool which
when used in conjunction with standard of care visual skin
assessment provides more reliable skin assessment and improved
documentation. The images the scanner generates can also help
facilities to initiate targeted preventative intervention earlier,
frequently avoiding pressure ulcers from developing. Paul Wilson,
President of Longport, Inc. said �The Company believes that the
door into acute care is beginning to open for the EPISCAN. We
project acute care will become one of Longport�s largest markets.
In addition to the sales reported, the Company has received
inquiries from numerous acute hospitals each potentially looking to
purchase multiple systems.� Longport will also be exhibiting at the
Clinical Symposium on Advances in Skin and Wound Care, to be held
October 26 - 30 in Las Vegas. This symposium targets nurses,
physicians, podiatrists, physical therapists, dietitians, and
others who manage skin and wound care patients across the continuum
of health care. Longport will be exhibiting at Booth 213. About
Longport, Inc. Longport, Inc. of Glen Mills, Pennsylvania, is a
medical technology company that specializes in high resolution
ultrasound imaging. After several years and a multi-million dollar
investment in the technology, Longport has secured patents,
copyrights and FDA permission to market. The Company�s technology
has been used to engineer a unique high resolution ultrasound
imaging system. For further information please contact Longport,
Inc. at 1-800-289-6863 or visit our website at www.longportinc.com.
Forward-looking Information and the Private Securities Litigation
Reform Act of 1995 Certain statements in this press release,
including statements concerning product development milestones and
anticipated events, are �forward-looking statements� within the
Private Litigation Reform Act of 1995. Forward Looking Statements
are based on the opinions and estimates of management at the time
the statements are made and are subject to certain risks and
uncertainties that could cause actual results to differ materially
from those anticipated in the forward-looking statements. The words
�believe,� �expect,� �intend,� �anticipate,� variations of such
words, and similar expressions identify forward-looking statements,
but their absence does not mean that the statement is not
forward-looking. These statements are not guarantees of future
performance and are subject to certain risks, uncertainties and
assumptions that are difficult to predict. Factors that could
affect Longport�s actual results include, among others,
uncertainties as to the Company�s ability to manage potential
problems, delays or anticipated expenses, including problems,
delays or expenses involving manufacturing. Readers are cautioned
not to place undue reliance upon these forward-looking statements
that speak only to the date of this release. Reference is made to
Longport�s 2004 annual report on Form 10-K filed with the
Securities and Exchange Commission for a more definitive
description of such factors. Longport, Inc. undertakes no
obligation to update publicly any forward-looking statements to
reflect new information, events or circumstances after the date of
this release or to reflect the occurrence of unanticipated events.
Longport (CE) (USOTC:LPTI)
과거 데이터 주식 차트
부터 11월(11) 2024 으로 12월(12) 2024
Longport (CE) (USOTC:LPTI)
과거 데이터 주식 차트
부터 12월(12) 2023 으로 12월(12) 2024
Longport Inc (CE) (OTC 시장)의 실시간 뉴스: 최근 기사 0
More Longport, Inc. News Articles